Adial Pharmaceuticals Inc (ADIL)

$0.23 0.00 (-0.88%)
Market Cap 6.31M
Revenue (ttm) 0.00
Net Income (ttm) -13.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 255,900
Avg Vol 343,018
Day's Range N/A - N/A
Shares Out 27.78M
Stochastic %K 30%
Beta 1.19
Analysts Strong Sell
Price Target $2.17

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 804 487 8196
Address:
4870 Sadler Road, Suite 300, Glen Allen, United States
kedute
kedute Jan. 16 at 7:36 PM
$FIG today draw some ux sketches - screenshot to gpt > figma promt > figma make - weeks work almost done, sure need fine tuning by hand, but it works. So can buy some $FIG as thank you & have early glass of aquavit 🥃 + need to add some $ADIL cause that’s why that
0 · Reply
StayPresent
StayPresent Jan. 16 at 5:55 PM
$ADIL 2/26 vote to approve further dilution. This needs to move before then or this will get very ugly.
1 · Reply
Tunes444
Tunes444 Jan. 16 at 4:25 PM
$ADIL
0 · Reply
Magnificent77
Magnificent77 Jan. 15 at 7:22 PM
$ADIL marked as strong buy by Zacks and at this much of a discount?? lets go!!!
1 · Reply
Tunes444
Tunes444 Jan. 15 at 1:56 PM
$ADIL Hoping we can get some sort of update about how theyre progressing on the trials/prep
0 · Reply
KiingDrew
KiingDrew Jan. 15 at 1:50 PM
$ADIL Feels like a speculative swing with real catalysts coming up
0 · Reply
PTI127
PTI127 Jan. 15 at 10:54 AM
$ADIL
0 · Reply
Perfect_Thinking
Perfect_Thinking Jan. 14 at 10:19 PM
$ADIL Its very interesting brought my avg .0.29 with 42k holding tight stop, hopefully in first week of feb 26 we will have some inputs of phase 3 and new CEO
2 · Reply
Risk1123
Risk1123 Jan. 14 at 6:17 PM
$ADIL Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 https://ca.finance.yahoo.com/news/adial-pharmaceuticals-announces-publication-international-140000411.html
1 · Reply
kedute
kedute Jan. 14 at 2:43 PM
$ADIL filled @0.21 - next stop local pub
1 · Reply
Latest News on ADIL
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Oct 17, 2025, 9:00 AM EDT - 3 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Oct 9, 2025, 8:30 AM EDT - 3 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Sep 16, 2025, 8:00 AM EDT - 4 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:30 AM EDT - 5 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Aug 6, 2025, 8:00 AM EDT - 5 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 16, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 13, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 2, 2025, 11:48 AM EDT - 9 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

May 1, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Mar 4, 2025, 8:30 AM EST - 11 months ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 25, 2025, 9:00 AM EST - 11 months ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 19, 2025, 9:00 AM EST - 11 months ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Feb 12, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jan 29, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 29, 2024, 8:30 AM EDT - 1 year ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 2:15 PM EDT - 1 year ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Mar 1, 2024, 7:00 PM EST - 2 years ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 28, 2024, 9:30 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 24, 2023, 4:30 PM EDT - 2 years ago

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Oct 19, 2023, 12:00 PM EDT - 2 years ago

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Oct 19, 2023, 10:30 AM EDT - 2 years ago

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

kedute
kedute Jan. 16 at 7:36 PM
$FIG today draw some ux sketches - screenshot to gpt > figma promt > figma make - weeks work almost done, sure need fine tuning by hand, but it works. So can buy some $FIG as thank you & have early glass of aquavit 🥃 + need to add some $ADIL cause that’s why that
0 · Reply
StayPresent
StayPresent Jan. 16 at 5:55 PM
$ADIL 2/26 vote to approve further dilution. This needs to move before then or this will get very ugly.
1 · Reply
Tunes444
Tunes444 Jan. 16 at 4:25 PM
$ADIL
0 · Reply
Magnificent77
Magnificent77 Jan. 15 at 7:22 PM
$ADIL marked as strong buy by Zacks and at this much of a discount?? lets go!!!
1 · Reply
Tunes444
Tunes444 Jan. 15 at 1:56 PM
$ADIL Hoping we can get some sort of update about how theyre progressing on the trials/prep
0 · Reply
KiingDrew
KiingDrew Jan. 15 at 1:50 PM
$ADIL Feels like a speculative swing with real catalysts coming up
0 · Reply
PTI127
PTI127 Jan. 15 at 10:54 AM
$ADIL
0 · Reply
Perfect_Thinking
Perfect_Thinking Jan. 14 at 10:19 PM
$ADIL Its very interesting brought my avg .0.29 with 42k holding tight stop, hopefully in first week of feb 26 we will have some inputs of phase 3 and new CEO
2 · Reply
Risk1123
Risk1123 Jan. 14 at 6:17 PM
$ADIL Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 https://ca.finance.yahoo.com/news/adial-pharmaceuticals-announces-publication-international-140000411.html
1 · Reply
kedute
kedute Jan. 14 at 2:43 PM
$ADIL filled @0.21 - next stop local pub
1 · Reply
JohnTrack
JohnTrack Jan. 14 at 2:38 PM
$ADIL new item on the tape https://www.rapidticker.com/news/adil-adial-pharmaceuticals-announces-publication-of-fc3d99
0 · Reply
Tunes444
Tunes444 Jan. 14 at 2:34 PM
$ADIL currently in Phase III prep
1 · Reply
Perfect_Thinking
Perfect_Thinking Jan. 14 at 2:34 PM
$ADIL
0 · Reply
DARKP00L
DARKP00L Jan. 14 at 2:13 PM
$ADIL 09:03 on Jan. 14 2026 Adial Pharmaceuticals Publishes International Patent Application For AD04 Serotonin-3 Receptor Antagonist Therapeutic Agent To Treat Alcohol Use Disorder #tradeideas
0 · Reply
kedute
kedute Jan. 13 at 11:29 PM
$ADIL can’t fill my glass at 0.22 Nor good - nor bad
0 · Reply
Bhaddar1
Bhaddar1 Jan. 13 at 10:36 PM
$ADIL. Lets go baby
0 · Reply
DarkSonar
DarkSonar Jan. 13 at 3:40 PM
$ADIL Out of this with tiny loss!! Volume just not showing up for this and have better plays with higher potential
2 · Reply
StayPresent
StayPresent Jan. 13 at 3:15 PM
$ADIL Heavy dilution on the way. This looks headed for the .05 range. Couple that with a ‘coming soon’ 1:25 RS and we are toast here. They are broke and can’t possibly be in position to successfully run a phase 3 now or in the immediate future. Took a big loss here. GLTA
0 · Reply
StayPresent
StayPresent Jan. 13 at 11:39 AM
$ADIL Adial Pharmaceuticals Faces 50% Share Dilution in $4.3 Million Capital Drive https://www.panabee.com/news/adial-pharmaceuticals-executive-compensation-2026
0 · Reply
Perfect_Thinking
Perfect_Thinking Jan. 12 at 7:58 PM
$ADIL Its been while waiting for new CEO OPionte and news of 3rd phase a great combo, its staying by 6.5 mil support MC, hopefully need a push from here..
0 · Reply
StayPresent
StayPresent Jan. 12 at 7:38 PM
$ADIL RS Incoming?
0 · Reply
DarkSonar
DarkSonar Jan. 12 at 5:34 PM
$ADIL Broke trend!! When will this run? It’s been a while since giving us a nice parabolic move. I would love to catch it in action mode. Still holding small position. 😬
0 · Reply